Supplier News Breaks Archives
CHPA names regulatory, science directors
January 17th, 2012
WASHINGTON – The Consumer Healthcare Products Association (CHPA) has appointed John Punzi and Jay Sirois as directors in its regulatory and scientific affairs department.
CHPA said Monday that Punzi serves as director of quality assurance and technical affairs, and Sirois takes the post of director of regulatory and scientific affairs.
In his new role, Punzi will coordinate CHPA's Product Quality and Operations Workshop and serve as the CHPA liaison to the Manufacturing Controls Committee and its subcommittees. In addition, he acts as the association's industry liaison to standards-setting agencies, including the U.S. Pharmacopeia (USP), and oversees the industry’s involvement in USP monograph modernization. Punzi represents CHPA member companies as their delegate to the 2015 USP Convention.
Before coming to CHPA, Punzi worked for more than nine years as a senior chemist in the science and technology division of the U.S. Department of Agriculture and for five years in the health effects division of the Environmental Protection Agency.
Meanwhile, Sirois is responsible for CHPA's regulatory and scientific affairs activities, including cooperative programs with the Food and Drug Administration, ingredient safety, and dietary supplement programs at CHPA. Prior to joining CHPA, he was director of scientific research and clinical studies at Pharmaceutical Development Group. CHPA noted that Sirois is experienced in pharmaceutical, medical device, and dietary supplement regulatory affairs, pharmacovigilance, prescription to over-the-counter switches, product safety and clinical research.
"I'm thrilled to have such a strong and diverse team in regulatory and scientific affairs," stated CHPA vice president Barbara Kochanowski, who leads the department. "We have a variety of projects where Jay's regulatory and pharmacology expertise can be immediately applied. John's chemistry and government team leadership skills will be critical in moving ahead our work with FDA and USP to modernize ingredient monographs, a priority project."